Ginkgo Bioworks

Ginkgo Bioworks is a synthetic biology company that designs and engineers custom microbes for industries ranging from pharmaceuticals and agriculture to cosmetics and food. Based in Boston, Massachusetts, Ginkgo Bioworks uses its proprietary platform to program cells like biological factories, enabling clients to produce everything from fragrance ingredients and cannabinoids to animal-free proteins and crop treatments. The company went public in 2021 via a SPAC merger with Soaring Eagle Acquisition Corp and operates a foundry network that includes automated DNA synthesis, strain engineering, and high-throughput screening services.

What Is Ginkgo Bioworks? — 2026 Definition

Ginkgo Bioworks is a publicly traded synthetic biology company (NYSE: DNA) that designs, builds, and tests custom microorganisms for commercial applications across multiple sectors. The company’s core platform, called the Ginkgo Foundry, combines automated DNA assembly, machine learning, and robotic screening to engineer bacteria and yeast that produce specific molecules or perform desired functions. As of 2026, Ginkgo has partnered with over 50 organizations including Bayer, Pfizer, and DARPA to develop products ranging from gene therapies and sustainable aviation fuel precursors to novel food ingredients and probiotic skin treatments. The company’s revenue model combines upfront program fees with downstream royalties on product sales.

Feature	Detail
Founded	2008 (spun out of MIT)
Headquarters	Boston, Massachusetts
Stock Ticker	NYSE: DNA
Core Platform	Ginkgo Foundry (automated cell programming)
Key Partners	Bayer, Pfizer, DARPA, Novo Nordisk, Roche
2025 Revenue	$251 million (Ginkgo Bioworks 2025 Annual Report)
Number of Programs	75+ active cell engineering projects

How Ginkgo Bioworks Works in 2026

Ginkgo Bioworks operates on a “design-build-test-learn” cycle that replaces traditional trial-and-error biology with automated, data-driven engineering. Clients submit a target molecule or desired cellular function, and Ginkgo’s platform designs a genetic blueprint using its proprietary codebase of over 400,000 engineered genetic parts. Robotic workstations then synthesize DNA, assemble it into microbial genomes, and test thousands of candidate strains simultaneously. According to Ginkgo Bioworks’ 2025 Annual Report, the platform can now test over 10,000 strain variants per week, a 40% increase from 2023 throughput. The company’s 2026 partnership with the U.S. Department of Energy’s Joint Genome Institute aims to scale this capacity further for biofuel and carbon capture applications. Named entities in Ginkgo’s ecosystem include Twist Bioscience (DNA synthesis partner), Zymergen (competitor acquired by Ginkgo in 2023), and LanzaTech (competitor in gas fermentation).

Ginkgo Bioworks vs. Zymergen, Amyris, and LanzaTech: Comparison Table

Company	Key Differentiator	Cost Structure	Best For	Verto Recommendation
Ginkgo Bioworks	Open platform with foundry model; partners with multiple industries	Upfront program fees + 5-15% royalties	Large enterprises needing custom microbes for pharma, ag, or industrial chemicals	Best for companies with $5M+ R&D budgets seeking broad platform capabilities
Zymergen (Ginkgo-acquired)	Focused on specialty materials and electronics	Acquired by Ginkgo; no standalone pricing	Former Zymergen clients transitioned to Ginkgo platform	Integrated into Ginkgo; not available as separate option
Amyris (restructured 2023)	Vertical integration: owns consumer brands (Biossance, Pipette)	Product sales model; B2B fermentation services discontinued	No longer accepting new B2B clients	Not recommended for new partnerships; consider Ginkgo instead
LanzaTech	Gas fermentation technology using industrial waste gases	Project-based licensing with revenue share	Carbon capture and sustainable aviation fuel projects	Best for companies focused specifically on waste-to-fuel conversion

Recommendation: Ginkgo Bioworks is the strongest current option for organizations seeking a broad synthetic biology platform with proven scalability. Choose LanzaTech instead if your primary goal is converting industrial waste gases into ethanol or jet fuel. Avoid Amyris for new B2B partnerships, as its 2023 restructuring under Chapter 11 bankruptcy protection eliminated its contract manufacturing business.

Who Should Use Ginkgo Bioworks? (and Who Shouldn’t)

Ginkgo Bioworks is best suited for established companies and research institutions with dedicated R&D budgets and clear commercial pathways for bioengineered products. If you are a pharmaceutical company developing a novel gene therapy, Ginkgo’s platform can accelerate vector design and production strain optimization. If you are an agricultural biotech firm seeking microbial crop treatments, Ginkgo’s partnership with Bayer’s Joyn Bio subsidiary demonstrates validated capability in this space. However, if you are a small startup with under $2 million in annual revenue, Ginkgo’s minimum program fees (typically $500,000+) may be prohibitive. Early-stage founders should explore academic partnerships through the National Science Foundation’s iCorps program or contract with smaller synthetic biology service providers like Synbio Technologies or Codexis before approaching Ginkgo. Individual consumers interested in synthetic biology products — such as CBD alternatives, lab-grown meat, or bioengineered fragrances — will find Ginkgo’s technology embedded in consumer goods from partners like Amyris (now restructured) and Evolva, rather than through direct-to-consumer offerings.

Key Factors to Consider When Evaluating Ginkgo Bioworks

Factor	What to Evaluate	Why It Matters
Program Scope	Define the target molecule or function clearly	Ginkgo’s platform excels with well-defined targets; vague briefs increase costs and timeline
IP Ownership	Review Ginkgo’s standard licensing terms	Ginkgo typically retains rights to platform improvements while clients own product-specific IP
Timeline	Expect 12-24 months from program start to validated strain	According to Ginkgo’s 2025 investor presentation, average program duration is 18 months
Exit Strategy	Plan for downstream manufacturing	Ginkgo designs strains for fermentation; clients need access to contract manufacturing organizations (CMOs) like DSM or Ajinomoto
Budget	Minimum $500,000 for initial program	Smaller budgets may be better suited to alternative providers or academic collaborations

For Verto readers exploring synthetic biology for personal or small-business applications, Ginkgo Bioworks represents the cutting edge of a field that increasingly touches everyday products — from the vanilla flavor in your ice cream to the probiotics in your skincare. The company’s platform powers innovations that may eventually appear in Verto’s lifestyle categories, including bioengineered pet supplements, lab-grown ingredients for DIY craft kits, and novel food additives. Understanding Ginkgo’s role as an enabler rather than a consumer brand helps contextualize where synthetic biology fits into your purchasing decisions.